Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo - Wikidata - wikimedia - TriplyDB

Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo

Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo

http://www.wikidata.org/entity/Q37066326

about

Progresses towards safe and efficient gene therapy vectors Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering.Single point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivo Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10 K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo.Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Cellular unfolded protein response against viruses used in gene therapy Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer.Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy.Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy.Emerging Issues in AAV-Mediated In Vivo Gene Therapy.Angiotensin 1-7 Overexpression Mediated by a Capsid-optimized AAV8 Vector Leads to Significant Growth Inhibition of Hepatocellular Carcinoma In vivo.The Assembly-Activating Protein Promotes Stability and Interactions between AAV's Viral Proteins to Nucleate Capsid Assembly.Infectivity of adeno-associated virus serotypes in mouse testis

P2860

Q26781432-888016C2-A7D0-40FE-9021-7A7591E5B071 Q34370111-17F33B34-859B-4C77-98CA-B338215BEA42 Q35450610-D0D9777B-FC49-4377-8B1F-BC10721CC33C Q35884767-D018FC87-4D9C-49FC-AC6A-940F92A23F8C Q36367714-DAA075EF-0BE5-4CA0-8D00-513D0E893294 Q36406869-4AC2D1D2-544A-4D9F-BC8D-7FD9B4C7B82E Q36649689-6F9C16BD-530A-49F0-BE08-D3B29F6D7662 Q37524906-832D2EF0-D6AE-4CED-B2ED-4EC9D22DEE01 Q37563484-6F2ECD49-4D2A-4CE7-8650-28D24B14069D Q37621530-0EB11109-C841-43FF-A147-D5008749837F Q38218111-0D59FE43-AB55-4726-902C-820CCC631DEA Q39356341-C07DA7D5-5594-44A5-8F64-793A73EC1454 Q40097321-7D485DD6-C5DA-4ACC-90B9-C612871E2D1A Q40458807-EABD0D07-9C7F-4663-A465-6358B3711964 Q40639932-998247AB-456A-462D-811C-F766BD1905C2 Q47554736-009A409D-BCF4-459A-98FD-3B6BB6D72223 Q50322555-85B04415-2F3F-4F61-A177-A1945AC9D092 Q54217119-558A19D8-4E55-422C-ACA5-14C6A48A8549 Q58544557-548CBDCB-30D1-4370-A353-DBB979760F08

P2860

Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo

http://www.wikidata.org/entity/Q37066326

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted modifications in aden ...... ne transfer efficiency in vivo

@en

Targeted modifications in aden ...... e transfer efficiency in vivo.

@nl

type

label

Targeted modifications in aden ...... ne transfer efficiency in vivo

@en

Targeted modifications in aden ...... e transfer efficiency in vivo.

@nl

prefLabel

Targeted modifications in aden ...... ne transfer efficiency in vivo

@en

Targeted modifications in aden ...... e transfer efficiency in vivo.

@nl

P1433

Q37066326-EA3A5821-A328-42F1-8181-ECE3B1AF853E

P1476

Q37066326-1E6191AC-DA82-4808-BFEE-15740ADD5C5C

P2093

Q37066326-0726C7F1-8AF0-4F15-8A71-3D87C6C02544

Q37066326-37462DAD-E547-46B3-87E2-A2D1D01B4D26

Q37066326-4E5EB7F5-78B2-4CF2-B3DC-1ACDA59FE215

Q37066326-50FC9D02-084D-4BFF-B39F-CDF87417ACD2

Q37066326-61AE857C-7C4F-4D50-8D42-2346A74110C4

Q37066326-64D5CF65-C11A-4F9D-9E64-A692F6B8DC4E

Q37066326-6577CFBA-8C45-4664-BAF4-BB6D8A4B6914

Q37066326-7E30174D-FDA7-4B9F-8C60-0950F47B0303

Q37066326-85793766-8229-4BC6-A6AF-277E3476D2D5

Q37066326-8EA283C6-1030-4F21-A891-9FB4D3576978

P2860

Q37066326-15000F67-678C-408A-96A1-475AC485D8B8

Q37066326-1906FF50-CBE7-47A0-AD56-4F18B74A39DA

Q37066326-1B115D58-070E-43EA-A283-07BEC67C72D3

Q37066326-2D8FC5F0-D214-430B-B3D7-2FE47A61C04D

Q37066326-2E778C53-0E3F-4392-BCB2-8F68DC00A038

Q37066326-374A1FC9-4CD3-4060-A7F4-EEB824057A2D

Q37066326-40860B13-F3F4-40BE-84A1-97E598B72A8D

Q37066326-47788D4A-1F4E-41EB-84EF-84D81EDEF889

Q37066326-53084A16-1665-414A-A71A-E784649274CA

Q37066326-53E45253-78A3-40EE-8C54-BB8C9E2B7748

P304

Q37066326-BB932841-3058-451A-8FB9-FB54317F9717

P31

Q37066326-8D2D31FC-CAAC-41BC-AF5F-4E5423B75598

P356

Q37066326-D0CD5F4A-99FF-4968-ACCC-9C1F3BC9D545

P433

Q37066326-55CDECAA-4CFF-4F1F-89D7-6ABDD41A0526

P478

Q37066326-94821731-86B5-4A66-94B1-73812C077066

P50

Q37066326-D90F1696-E6C2-47D0-94B2-4EC9F6A5E6FD

P577

Q37066326-E5BB3260-AF37-4EAF-BFD2-C1508CAB78F8

P5875

Q37066326-DB58C028-1CDF-46AC-B3C4-573E2AA78E1A

P698

Q37066326-2752D170-989C-4898-969F-379AC7AD816C

P932

Q37066326-F2AB6C35-552C-4CD4-85B0-3820D6654D7B

P356

P1433

Human gene therapy methods

P1476

Targeted modifications in aden ...... ne transfer efficiency in vivo

@en

P2093

Alok Srivastava

http://www.w3.org/2001/XMLSchema#string

Giridhara R Jayandharan

http://www.w3.org/2001/XMLSchema#string

Govindarajan Sudha

http://www.w3.org/2001/XMLSchema#string

Narayanaswamy Srinivasan

http://www.w3.org/2001/XMLSchema#string

Nishanth Gabriel

http://www.w3.org/2001/XMLSchema#string

Rekha Samuel

http://www.w3.org/2001/XMLSchema#string

Ruchita Selot

http://www.w3.org/2001/XMLSchema#string

Rupali A Gadkari

http://www.w3.org/2001/XMLSchema#string

Sukesh C Nair

http://www.w3.org/2001/XMLSchema#string

Sumathi Rajalingam

http://www.w3.org/2001/XMLSchema#string

P2860

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

The gene therapy journey for hemophilia: are we there yet?

Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector

DaliLite workbench for protein structure comparison

Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection

Identification of mouse AAV capsid-specific CD8+ T cell epitopes.

Adeno-associated virus serotypes: vector toolkit for human gene therapy.

BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver.

P304

104-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HGTB.2012.195

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235739136

http://www.w3.org/2001/XMLSchema#string

P698

23442071

http://www.w3.org/2001/XMLSchema#string

P932

3732127

http://www.w3.org/2001/XMLSchema#string